Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02WBU
|
|||
| Former ID |
DNC008220
|
|||
| Drug Name |
2,2-diMeBut-RYYRIK-NH2
|
|||
| Synonyms |
CHEMBL403588
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C48H78N14O8
|
|||
| Canonical SMILES |
CCC(C)C(C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC1=CC=C(C=C1)O)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)(C)CC
|
|||
| InChI |
1S/C48H78N14O8/c1-6-29(3)38(44(69)57-33(39(50)64)17-11-12-24-49)62-41(66)34(18-13-25-55-46(51)52)58-42(67)37(28-31-20-22-32(63)23-21-31)60-43(68)36(27-30-15-9-8-10-16-30)59-40(65)35(19-14-26-56-47(53)54)61-45(70)48(4,5)7-2/h8-10,15-16,20-23,29,33-38,63H,6-7,11-14,17-19,24-28,49H2,1-5H3,(H2,50,64)(H,57,69)(H,58,67)(H,59,65)(H,60,68)(H,61,70)(H,62,66)(H4,51,52,55)(H4,53,54,56)/t29-,33-,34-,35-,36-,37-,38-/m0/s1
|
|||
| InChIKey |
JOZALXQUIMQHHA-AVTNSMPVSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nociceptin receptor (OPRL1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Designed modification of partial agonist of ORL1 nociceptin receptor for conversion into highly potent antagonist. Bioorg Med Chem. 2008 Mar 1;16(5):2635-44. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.